Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
Phase 3 N=230 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Phase 2 N=40 Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 2 N=30 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Phase 2 N=20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Mixed Gliomas
Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants
Phase 1 N=9 Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Glioblastoma Multiforme/Anaplastic Astrocytoma
Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2
Phase 2 N=11 Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Phase 2 N=60 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
CNS Cancer · CNS BRAIN
Primary: Progession Free Survival — 85.7 % of participants without progression
Phase 1 N=71 Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
Astrocytoma, Grade III · Glioblastoma
Primary: Maximum Tolerated Dose (MTD) — 150; 150 mg
Phase 2 N=74 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
Anaplastic Glioma of Brain · Glioblastoma Multiforme · Brain Cancer
Primary: 12 Month-progression-free Survival for Participants With Anaplastic Tumors — 44 percentage of participants
Phase 2 N=11 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Glioblastoma Multiforme · Anaplastic Astrocytoma
Primary: Safety of Twice a Day Oral 150 mg Erlotinib Dosing — 9 participants
Phase 2 N=72 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Phase 2 N=20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Phase 3 N=562 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Brain and Central Nervous System Tumors
Primary: Overall Survival — 9.33; 7.62 Months
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Tumors
Refractory Brain Tumors
Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants
Phase 2 N=85 Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Glioblastoma · Gliomas
Primary: 12 Month Overall Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concurrent Temozolomide and Radiotherapy Followed by Dose Dense or…
Phase 1 N=17 Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Ependymoma · Adult Anaplastic Oligodendroglioma
Primary: Maximum Tolerated Dose (MTD) of Alisertib — 50 mg dose of Alisertib
Phase 2 N=55 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Brain and Central Nervous System Tumors
Primary: Proportion of Participants With Objective Response Rate (ORR) — 5 Participants
Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=41 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate — 22 percentage of participants
N/A N=20 Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Adult Glioblastoma
Primary: Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery — 15 Participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=41 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Glioblastoma · Gliosarcoma
Primary: Response Rate — 24.4 percentage of patients
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants